Fig. 3: ATG9A ablation enhances macrophage-mediated tumor control in vivo.
From: Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity
A, B NSG Mice bearing control (CT) or ATG9A knockout (KO) subcutaneous SKOV3 tumors were treated with IgG (n = 15), or Trastuzumab (n = 25). Tumor volume was monitored over time. Box plots show the median (center line), 25th–75th percentiles (box), and 2.5th–97.5th percentiles (whiskers), with all data plotted. Statistical significance was determined using two-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. C, D NSG Mice bearing control or KO subcutaneous SKOV3 tumors were treated with IgG (n = 13), or Trastuzumab (n = 14) in combination with clodronate (25 mg/kg) to deplete macrophages. Box plots show the median (center line), 25th–75th percentiles (box), and 2.5th–97.5th percentiles (whiskers), with all data plotted. Statistical significance was determined using two-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. E, F Schematic and results of an intraperitoneal (IP) SKOV3-luciferase tumor model treated with or without α-EphA2-CAR macrophages (CAR-Ms). Tumor burden was quantified via bioluminescence imaging once weekly (n = 10 for control, n = 15 for CAR-M group). Box plots show the median (center line), 25th–75th percentiles (box), and 2.5th–97.5th percentiles (whiskers), with all data plotted. Representative IVIS images are shown on the right. Statistical significance was determined using two-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. Some elements of this figure were created with BioRender.com and are included under a publication license in accordance with BioRender’s user agreement. Created in BioRender. DeSelm, C. (2025) https://BioRender.com/ddmwmhn.
